Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,429 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: opiates Clear all

Conditions: Healthy Volunteer, Opioid-use Disorder
Interventions: INDV-2000, Placebo, SUBOXONE® sublingual film; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Baltimore, Maryland • DeSoto, Texas • San Antonio, Texas

Conditions: Alcoholism, Smoking
Interventions: naltrexone (Revia), nicotine replacement patch; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 50 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteoarthritis
Interventions: celecoxib, Oxycodone, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Palo Alto, California • Stanford, California

Conditions: Periacetabular Osteotomy, Opiates
Interventions: Open-Label Placebo, Treatment as usual; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years to 40 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Depression
Interventions: Buprenorphine; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 50 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Heroin Dependence, Morphine Dependence, Substance Withdrawal Syndrome
Interventions: Buprenorphine/naloxone; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 15 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 6
States / cities: Rancho Mirage, California • Orlando, Florida • Pinellas Park, Florida + 3 more

Conditions: Opioid Use, Opioid Use Disorder, Risk Reduction, Hiv, Hepatitis C
Interventions: Suboxone, Truvada, Mavyret; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Durham, North Carolina • Greensboro, North Carolina

Conditions: Alcoholism, Alcohol Drinking, Alcohol Dependence
Interventions: Naltrexone, placebo; Drug
Lead sponsor: UConn Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Opioid-Related Disorders, Substance-Related Disorders
Interventions: Buprenorphine; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 21 Years to 55 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2007
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Opioid Dependence
Interventions: Probuphine (buprenorphine implant), Sublingual Buprenorphine; Drug
Lead sponsor: Titan Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Hypogonadotropic Hypogonadism
Interventions: Kisspeptin 112-121, Naloxone, GnRH; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Opioid Use Disorder
Interventions: Suboxone, Brief counseling in the ED, Referral to outpatient treatment, Follow-up coaching; Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Opiate Substitution Treatment, Opioid-Related Disorders
Interventions: Liraglutide Pen Injector, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Hepatitis C, Opioid-Related Disorders
Interventions: telaprevir, buprenorphine/naloxone; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 2
States / cities: Overland Park, Kansas • Salt Lake City, Utah

Conditions: Pain, Postoperative, Arthroplasty, Replacement, Knee, Osteoarthritis
Interventions: Liposomal bupivacaine, bupivacaine HCl, morphine, epinephrine, methylprednisolone; Drug
Lead sponsor: Miller Orthopedic Specialists; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Council Bluffs, Iowa

Conditions: Driving Behavior
Interventions: Xanax 1Mg Tablet, Norco 10Mg-325Mg Tablet, Placebo Oral Tablet; Drug
Lead sponsor: Timothy L. Brown; Other
Eligibility: 18 Years to 40 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Pain
Interventions: Hydrocodone/Acetaminophen Extended Release, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Austin, Texas • Houston, Texas • San Antonio, Texas + 2 more

Conditions: Narcotic Use, Pain, Constipation, Nausea
Interventions: Celebrex, Gabapentin, IV acetaminophen, oral acetaminophen, oral ibuprofen, percocet, vicodin, Oxycodone, dilaudid, Dexamethasone, zofran; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Gastroesophageal Cancer
Interventions: Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan, Paclitaxel, Docetaxel, Rescue medications, Supportive care measures; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 17
States / cities: Gilbert, Arizona • Los Angeles, California • Orlando, Florida + 13 more

Conditions: Healthy
Interventions: Dextromethorphan HBr, GC4419; Drug
Lead sponsor: Galera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Low Back Pain
Interventions: Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 149
States / cities: Alabaster, Alabama • Birmingham, Alabama • Foley, Alabama + 114 more

Conditions: Alcohol Use Disorder
Interventions: Placebo, Glucagon-Like Peptide-1 Agonist (GLP-1), Naltrexone (oral tablets); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Havre de Grace, Maryland

Conditions: Pain
Interventions: Morphine, Ketamine; Drug
Lead sponsor: Antonios Likourezos; Other
Eligibility: 65 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Opioid-use Disorder
Interventions: TM buprenorphine, SUBLOCADE; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Berlin, New Jersey

Search by objective public record fields.

Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder

Behavioral/Drug Therapy for Alcohol-Nicotine Dependence (Naltrexone/Nicotine Patch)

Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.

Open-label Placebo for Pain Management in Adolescents and Young Adults Undergoing Bernese Periacetabular Osteotomy

Buprenorphine for Late-Life Treatment Resistant Depression

Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1

Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP

Targeted Naltrexone for Problem Drinkers

Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1

A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence

Neuropeptides in Human Reproduction

Houston Emergency Opioid Engagement System

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

Drug-Drug Interaction Study Between Telaprevir and Buprenorphine

Liposomal Bupivacaine in Total Knee Arthroplasty

Opiates and Benzodiazepines on Driving

A Study of Extended-Release Hydrocodone/Acetaminophen (Vicodin CR®) in Subjects With Acute Pain Following Bunionectomy

Decreasing Narcotics in Advanced Pelvic Surgery

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

Combination Therapy for Alcohol Use Disorder

Geriatric Ketamine for Pain Management Study

SUBLOCADE Rapid Initiation Study